Review

pdz usp28 flag (Addgene inc)

Addgene inc is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Addgene inc pdz usp28 flag
Pdz Usp28 Flag, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdz usp28 flag/product/Addgene inc
Average 91 stars, based on 8 article reviews

pdz usp28 flag - by Bioz Stars, 2026-05

91/100 stars

Images

Image Search Results

USP28 regulates MAST1 protein levels. A Transfection of an entire set of sgRNAs targeting individual USP subfamily genes along with Cas9 nuclease into cisplatin-resistant HeLa cells (HeLa-cisR). Transfected cells were treated with a sub-lethal dose (5 µg/mL) of cisplatin. HeLa-cisR cells treated with saline served as the negative control (vehicle) and cisplatin-treated HeLa-cisR cells co-transfected with scrambled sgRNA and Cas9 served as the mock control. Cisplatin-induced cell death was estimated using a cell viability assay and represented as a graph. Data are presented as the mean and standard deviation of three independent experiments (n = 3). B The USP28-depleted cells were treated with an increasing concentrations of cisplatin (5 µg/mL, 10 µg/mL, 15 µg/mL, 20 µg/mL and 25 µg/mL) for 48 h, and cell viability was measured. The IC 50 values of cisplatin in HeLa-CisR mock and USP28-sgRNA transfected cells were 6.32 µg/mL and 3.97 µg/mL, respectively. C Schematic representation of the sgRNAs targeting exon 2 of USP28 gene. The red arrowheads indicate the positions of sgRNAs target site on the sense DNA strand. PAM sequences are indicated in bold blue font; USP28 sgRNA sequences are indicated in red font. D The validation of efficiency of sgRNAs targeting USP28 by transient co-transfection with Cas9 in HEK293 cells and immunoblotting with USP28 antibody. The protein band intensities were estimated using ImageJ software with reference to the GAPDH control (USP28/GAPDH) and presented below the blot. The effect of depleting USP28 on endogenous MAST1 protein was estimated in HEK293 cells. E Validation of sgRNA efficiency targeting USP28 gene by transient co-transfection with Cas9 and sgRNA1 or sgRNA2 into HEK293 cells followed by a T7E1 assay to determine the cleavage efficiency. The cleaved band intensity (indel %) obtained by T7E1 assay was measured using ImageJ software and indicated. Scrambled sgRNA transfected HEK293 cells were used as a control cells. The black arrowhead indicates the cleaved PCR amplicons. A549 cells were transfected with increasing concentrations of F Flag-USP28 and G Flag-USP28CA to validate its effect on endogenous MAST1 protein levels. H The effect of reconstitution of Flag-USP28 on endogenous MAST1 protein in USP28-depleted A549 cells was validated. The protein band intensities for F – H were estimated using ImageJ software with reference to the GAPDH control band (MAST1/GAPDH) and presented below the blot. HEK293 cells were transfected with constant amount of Myc-MAST1 and increasing concentrations of I Flag-USP28 and J Flag-USP28CA to validate its effect on exogenous Myc-MAST1 protein levels. K The effect of reconstitution of Flag-USP28 on Myc-MAST1 protein in USP28-depleted HEK293 cells was validated. The protein band intensities for I – K were estimated using ImageJ software with reference to the GAPDH control band (Myc-MAST1/GAPDH) and presented below the blot

Journal: Cellular and Molecular Life Sciences

Article Title: USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells

doi: 10.1007/s00018-024-05187-2

Figure Lengend Snippet: USP28 regulates MAST1 protein levels. A Transfection of an entire set of sgRNAs targeting individual USP subfamily genes along with Cas9 nuclease into cisplatin-resistant HeLa cells (HeLa-cisR). Transfected cells were treated with a sub-lethal dose (5 µg/mL) of cisplatin. HeLa-cisR cells treated with saline served as the negative control (vehicle) and cisplatin-treated HeLa-cisR cells co-transfected with scrambled sgRNA and Cas9 served as the mock control. Cisplatin-induced cell death was estimated using a cell viability assay and represented as a graph. Data are presented as the mean and standard deviation of three independent experiments (n = 3). B The USP28-depleted cells were treated with an increasing concentrations of cisplatin (5 µg/mL, 10 µg/mL, 15 µg/mL, 20 µg/mL and 25 µg/mL) for 48 h, and cell viability was measured. The IC 50 values of cisplatin in HeLa-CisR mock and USP28-sgRNA transfected cells were 6.32 µg/mL and 3.97 µg/mL, respectively. C Schematic representation of the sgRNAs targeting exon 2 of USP28 gene. The red arrowheads indicate the positions of sgRNAs target site on the sense DNA strand. PAM sequences are indicated in bold blue font; USP28 sgRNA sequences are indicated in red font. D The validation of efficiency of sgRNAs targeting USP28 by transient co-transfection with Cas9 in HEK293 cells and immunoblotting with USP28 antibody. The protein band intensities were estimated using ImageJ software with reference to the GAPDH control (USP28/GAPDH) and presented below the blot. The effect of depleting USP28 on endogenous MAST1 protein was estimated in HEK293 cells. E Validation of sgRNA efficiency targeting USP28 gene by transient co-transfection with Cas9 and sgRNA1 or sgRNA2 into HEK293 cells followed by a T7E1 assay to determine the cleavage efficiency. The cleaved band intensity (indel %) obtained by T7E1 assay was measured using ImageJ software and indicated. Scrambled sgRNA transfected HEK293 cells were used as a control cells. The black arrowhead indicates the cleaved PCR amplicons. A549 cells were transfected with increasing concentrations of F Flag-USP28 and G Flag-USP28CA to validate its effect on endogenous MAST1 protein levels. H The effect of reconstitution of Flag-USP28 on endogenous MAST1 protein in USP28-depleted A549 cells was validated. The protein band intensities for F – H were estimated using ImageJ software with reference to the GAPDH control band (MAST1/GAPDH) and presented below the blot. HEK293 cells were transfected with constant amount of Myc-MAST1 and increasing concentrations of I Flag-USP28 and J Flag-USP28CA to validate its effect on exogenous Myc-MAST1 protein levels. K The effect of reconstitution of Flag-USP28 on Myc-MAST1 protein in USP28-depleted HEK293 cells was validated. The protein band intensities for I – K were estimated using ImageJ software with reference to the GAPDH control band (Myc-MAST1/GAPDH) and presented below the blot

Article Snippet: Flag-tagged USP28 (Addgene #15665) and HA-tagged Ubiquitin (Addgene #18712) plasmids were purchased from Addgene.

Techniques: Transfection, Saline, Negative Control, Viability Assay, Standard Deviation, Cotransfection, Western Blot, Software

USP28 interacts with MAST1 and extends its half-life. A The interaction between endogenous USP28 and MAST1 protein was analyzed in A549 by immunoprecipitation and immunoblotting using the specific antibodies. B Interaction between ectopically expressed USP28 and MAST1 was analyzed in HEK293 cells. Cells lysates were immunoprecipitated using Myc or Flag antibodies and analyzed by western blot. GAPDH was used as a loading control. C A549 cells were subjected to the Duolink PLA assay to analyze the interaction between USP28 and MAST1 using specific antibodies. The in situ USP28-MAST1 interaction (red PLA dots) was observed when USP28 and MAST1 were immunostained together but not when they were stained with individual antibodies. Scale bar: 10 µm. D–E The effect of USP28 and USP28CA on the half-life of Myc-MAST1 in HEK293 ( D ) and endogenous MAST1 ( E ) protein in A549 cells. CHX (150 μg/mL) was administered for the indicated time, and the cells were then harvested for western blotting with the indicated antibodies. The protein band intensities were estimated using ImageJ software with reference to the GAPDH control. Data are presented as the mean and standard deviation of three independent experiments (n = 3). A two-way ANOVA followed by Tukey's post hoc test was used, and P values are indicated

Journal: Cellular and Molecular Life Sciences

Article Title: USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells

doi: 10.1007/s00018-024-05187-2

Figure Lengend Snippet: USP28 interacts with MAST1 and extends its half-life. A The interaction between endogenous USP28 and MAST1 protein was analyzed in A549 by immunoprecipitation and immunoblotting using the specific antibodies. B Interaction between ectopically expressed USP28 and MAST1 was analyzed in HEK293 cells. Cells lysates were immunoprecipitated using Myc or Flag antibodies and analyzed by western blot. GAPDH was used as a loading control. C A549 cells were subjected to the Duolink PLA assay to analyze the interaction between USP28 and MAST1 using specific antibodies. The in situ USP28-MAST1 interaction (red PLA dots) was observed when USP28 and MAST1 were immunostained together but not when they were stained with individual antibodies. Scale bar: 10 µm. D–E The effect of USP28 and USP28CA on the half-life of Myc-MAST1 in HEK293 ( D ) and endogenous MAST1 ( E ) protein in A549 cells. CHX (150 μg/mL) was administered for the indicated time, and the cells were then harvested for western blotting with the indicated antibodies. The protein band intensities were estimated using ImageJ software with reference to the GAPDH control. Data are presented as the mean and standard deviation of three independent experiments (n = 3). A two-way ANOVA followed by Tukey's post hoc test was used, and P values are indicated

Article Snippet: Flag-tagged USP28 (Addgene #15665) and HA-tagged Ubiquitin (Addgene #18712) plasmids were purchased from Addgene.

Techniques: Immunoprecipitation, Western Blot, In Situ, Staining, Software, Standard Deviation

USP28 deubiquitinates MAST1 protein. The ubiquitination and deubiquitination of ectopically expressed Myc-MAST1 were analyzed in HEK293 cells. A The HEK293 cells were transfected with Myc-MAST1 and HA-Ub in a constant amount. Flag-USP28 was transfected in an increasing concentration, followed by immunoprecipitation with Myc antibody and immunoblotting with anti-HA antibody. B The ubiquitination and deubiquitination of ectopically expressed Myc-MAST1 were analyzed by transfecting HEK293 cells with Flag-USP28 and Flag-USP28CA or treatment with DUB-inhibitor PR-619 for 48 h prior to harvest in the HEK293 cells. The cells were harvested, followed by IP with a Myc antibody and immunoblotting with an anti-HA antibody. C The ubiquitination and deubiquitination of ectopically expressed Myc-MAST1 were analyzed by transfecting HEK293 cells with sgRNAs targeting USP28. The cells were harvested, followed by IP with a Myc antibody and immunoblotting with an anti-HA antibody. A – C The relative protein expression of MAST1-(Ub)n with respect to input MAST1 was quantified using ImageJ software and represented as (MAST1-(Ub)n/MAST1) below the blot. D Sanger sequencing data showing the disruption in USP28 gene sequence in A549 (upper panel) and H1299 cells (lower panel). The effect of USP28-KO on the mRNA expression of E USP28 and F MAST1 was evaluated by qRT-PCR with specific primers. The relative mRNA expression levels are shown after normalization to GAPDH mRNA expression. Data are presented as the mean and standard deviation of three independent experiments (n = 3). A two tailed t-test was used, and P values are indicated. G Flow cytometry assay showing the expression of USP28 in mock control vs. USP28-KO in A549 cells (left panel) and H1299 cells (right panel). H Western blot analysis of the endogenous expression of USP28 and MAST1 protein in A549 and H1299 USP28-KO was evaluated. GAPDH was used as the internal loading control. I The TUBEs assay was performed to assess the ubiquitination status of the MAST1 protein in mock control and USP28-KO clones from A549 and H1299 cells. Cell lysates were immunoprecipitated with TUBEs beads, followed by immunoblotting with the indicated antibodies. J–K The effect of USP28-KO on the half-life of MAST1 in A549 cells. The mock control, USP28-KO and USP28-KO cells reconstituted with ( J ) Flag-USP28 and K Flag-USP28CA was treated with CHX (150 μg/mL) for the indicated time, and the cells were then harvested for western blotting with the indicated antibodies. The protein band intensities were estimated using ImageJ software with reference to the GAPDH control

Journal: Cellular and Molecular Life Sciences

Article Title: USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells

doi: 10.1007/s00018-024-05187-2

Figure Lengend Snippet: USP28 deubiquitinates MAST1 protein. The ubiquitination and deubiquitination of ectopically expressed Myc-MAST1 were analyzed in HEK293 cells. A The HEK293 cells were transfected with Myc-MAST1 and HA-Ub in a constant amount. Flag-USP28 was transfected in an increasing concentration, followed by immunoprecipitation with Myc antibody and immunoblotting with anti-HA antibody. B The ubiquitination and deubiquitination of ectopically expressed Myc-MAST1 were analyzed by transfecting HEK293 cells with Flag-USP28 and Flag-USP28CA or treatment with DUB-inhibitor PR-619 for 48 h prior to harvest in the HEK293 cells. The cells were harvested, followed by IP with a Myc antibody and immunoblotting with an anti-HA antibody. C The ubiquitination and deubiquitination of ectopically expressed Myc-MAST1 were analyzed by transfecting HEK293 cells with sgRNAs targeting USP28. The cells were harvested, followed by IP with a Myc antibody and immunoblotting with an anti-HA antibody. A – C The relative protein expression of MAST1-(Ub)n with respect to input MAST1 was quantified using ImageJ software and represented as (MAST1-(Ub)n/MAST1) below the blot. D Sanger sequencing data showing the disruption in USP28 gene sequence in A549 (upper panel) and H1299 cells (lower panel). The effect of USP28-KO on the mRNA expression of E USP28 and F MAST1 was evaluated by qRT-PCR with specific primers. The relative mRNA expression levels are shown after normalization to GAPDH mRNA expression. Data are presented as the mean and standard deviation of three independent experiments (n = 3). A two tailed t-test was used, and P values are indicated. G Flow cytometry assay showing the expression of USP28 in mock control vs. USP28-KO in A549 cells (left panel) and H1299 cells (right panel). H Western blot analysis of the endogenous expression of USP28 and MAST1 protein in A549 and H1299 USP28-KO was evaluated. GAPDH was used as the internal loading control. I The TUBEs assay was performed to assess the ubiquitination status of the MAST1 protein in mock control and USP28-KO clones from A549 and H1299 cells. Cell lysates were immunoprecipitated with TUBEs beads, followed by immunoblotting with the indicated antibodies. J–K The effect of USP28-KO on the half-life of MAST1 in A549 cells. The mock control, USP28-KO and USP28-KO cells reconstituted with ( J ) Flag-USP28 and K Flag-USP28CA was treated with CHX (150 μg/mL) for the indicated time, and the cells were then harvested for western blotting with the indicated antibodies. The protein band intensities were estimated using ImageJ software with reference to the GAPDH control

Article Snippet: Flag-tagged USP28 (Addgene #15665) and HA-tagged Ubiquitin (Addgene #18712) plasmids were purchased from Addgene.

Techniques: Transfection, Concentration Assay, Immunoprecipitation, Western Blot, Expressing, Software, Sequencing, Disruption, Quantitative RT-PCR, Standard Deviation, Two Tailed Test, Flow Cytometry, Clone Assay

Correlation between USP28 and MAST1 expression in various cancers tissues. A Box plot showing difference between USP28 expression in tumor and normal tissues in LUSC, CESC, LIHC and ESCA cancer types. B Box plot showing difference between MAST1 expression in tumor and normal tissues in LUSC, CESC, LIHC and ESCA cancer types. The box plots (A-B) were generated using online bioinformatics tool GEPIA 2 ( http://gepia2.cancer-pku.cn/#index ). C A heat map showing mRNA expression levels of USP28 and MAST1 in different cancer cell lines derived from the CCLE database. Representative samples are arranged from high to low mRNA levels of USP28, and corresponding MAST1 values are sorted. D A scatterplot showing the expression correlation between USP28 and MAST1 mRNA levels in different cancer cell lines derived from the CCLE database. Pearson correlations (r) quantifying the relationship between USP28 and MAST1 are given. E Endogenous protein expression patterns of USP28 and MAST1 in different cancer and non-cancer cell lines were assessed by Western blotting. GAPDH was used as the loading control. F–H Representative immunohistochemical (IHC) staining images of endogenous USP28 and MAST1 in F human lung cancer (n = 27), G breast cancer (n = 18) and H colon cancer (n = 24) tissues. All IHC images were quantified with an H-score and difference in expression of MAST1 and USP28 in normal and tumor samples was represented graphically. Scale bar = 30 µm

Journal: Cellular and Molecular Life Sciences

Article Title: USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells

doi: 10.1007/s00018-024-05187-2

Figure Lengend Snippet: Correlation between USP28 and MAST1 expression in various cancers tissues. A Box plot showing difference between USP28 expression in tumor and normal tissues in LUSC, CESC, LIHC and ESCA cancer types. B Box plot showing difference between MAST1 expression in tumor and normal tissues in LUSC, CESC, LIHC and ESCA cancer types. The box plots (A-B) were generated using online bioinformatics tool GEPIA 2 ( http://gepia2.cancer-pku.cn/#index ). C A heat map showing mRNA expression levels of USP28 and MAST1 in different cancer cell lines derived from the CCLE database. Representative samples are arranged from high to low mRNA levels of USP28, and corresponding MAST1 values are sorted. D A scatterplot showing the expression correlation between USP28 and MAST1 mRNA levels in different cancer cell lines derived from the CCLE database. Pearson correlations (r) quantifying the relationship between USP28 and MAST1 are given. E Endogenous protein expression patterns of USP28 and MAST1 in different cancer and non-cancer cell lines were assessed by Western blotting. GAPDH was used as the loading control. F–H Representative immunohistochemical (IHC) staining images of endogenous USP28 and MAST1 in F human lung cancer (n = 27), G breast cancer (n = 18) and H colon cancer (n = 24) tissues. All IHC images were quantified with an H-score and difference in expression of MAST1 and USP28 in normal and tumor samples was represented graphically. Scale bar = 30 µm

Article Snippet: Flag-tagged USP28 (Addgene #15665) and HA-tagged Ubiquitin (Addgene #18712) plasmids were purchased from Addgene.

Techniques: Expressing, Generated, Derivative Assay, Western Blot, Immunohistochemical staining, Immunohistochemistry

Loss of USP28 suppresses cell viability and promotes DNA damage and apoptosis. Mock control, USP28-KO, and USP28-KO cells reconstituted with either USP28 or MAST1 were used to perform the following experiments. A Western blot analysis to validate the expression of USP28 and MAST1 using USP28- and MAST1-specific antibodies in A549 cells. The cells from A were subjected to the following experiments. B A549 cells were treated with an increasing concentration of cisplatin (5 µg/mL, 10 µg/mL, 15 µg/mL, 20 µg/mL and 25 µg/mL) for 48 h, and cell viability was assayed using CCK-8 reagent. Data are presented as the mean and standard deviation of three independent experiments (n = 3). The IC 50 values of cisplatin in A549 mock, USP28-KO, and USP28-KO reconstituted with USP28 and USP28-KO reconstituted with MAST1 were 3.56 µg/mL, 2.13 µg/mL, 3.36 µg/mL, and 3.44 µg/mL, respectively. C A549 cells were treated with cisplatin (2 µg/mL) for 48 h and subjected to flow cytometry to measure the DNA content using PI staining and Data are presented as the mean and standard deviation of three independent experiments (n = 3). D A549 cells were treated with either vehicle or Cisplatin (2 µg/mL) for 48 h and subjected to immunofluorescence analysis to estimate γH2AX foci formation. Green, γH2AX; blue, nucleus stained by DAPI. Scale bar = 100 µm. The right panel depicts the percentage of γH2AX-positive cells. Data are presented as the mean and standard deviation of three independent experiments (n = 3). E A549 cells treated with cisplatin (2 µg/mL) for 48 h were subjected to immunoblotting analysis with the indicated antibodies. The protein band intensities were estimated using ImageJ software with reference to the GAPDH control (γ-H2AX/GAPDH) and presented below the blot. F A549 cells were treated with the indicated concentrations of USP28 inhibitor (AZ1) with either vehicle or cisplatin (2 µg/mL) for 48 h and subjected to immunofluorescence analysis to estimate γH2AX foci formation. Green, γH2AX; blue, nucleus stained by DAPI. Scale bar = 100 µm. The right panel depicts the percentage of γH2AX-positive cells. Data are presented as the mean and standard deviation of three independent experiments (n = 3). G A549 cells were treated with cisplatin (2 µg/mL) for 48 h. Flow cytometry analysis was performed to analyze annexin-V and PI positive cells and graphically represented. Data are presented as the means and standard deviations of 3 independent experiments. H The effect of USP28 depletion or USP28 inhibitor (AZ1) on MEK pathway in A549 cells treated with cisplatin (2 µg/mL) by western blotting with indicated antibodies. GAPDH was used as the internal loading control

Journal: Cellular and Molecular Life Sciences

Article Title: USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells

doi: 10.1007/s00018-024-05187-2

Figure Lengend Snippet: Loss of USP28 suppresses cell viability and promotes DNA damage and apoptosis. Mock control, USP28-KO, and USP28-KO cells reconstituted with either USP28 or MAST1 were used to perform the following experiments. A Western blot analysis to validate the expression of USP28 and MAST1 using USP28- and MAST1-specific antibodies in A549 cells. The cells from A were subjected to the following experiments. B A549 cells were treated with an increasing concentration of cisplatin (5 µg/mL, 10 µg/mL, 15 µg/mL, 20 µg/mL and 25 µg/mL) for 48 h, and cell viability was assayed using CCK-8 reagent. Data are presented as the mean and standard deviation of three independent experiments (n = 3). The IC 50 values of cisplatin in A549 mock, USP28-KO, and USP28-KO reconstituted with USP28 and USP28-KO reconstituted with MAST1 were 3.56 µg/mL, 2.13 µg/mL, 3.36 µg/mL, and 3.44 µg/mL, respectively. C A549 cells were treated with cisplatin (2 µg/mL) for 48 h and subjected to flow cytometry to measure the DNA content using PI staining and Data are presented as the mean and standard deviation of three independent experiments (n = 3). D A549 cells were treated with either vehicle or Cisplatin (2 µg/mL) for 48 h and subjected to immunofluorescence analysis to estimate γH2AX foci formation. Green, γH2AX; blue, nucleus stained by DAPI. Scale bar = 100 µm. The right panel depicts the percentage of γH2AX-positive cells. Data are presented as the mean and standard deviation of three independent experiments (n = 3). E A549 cells treated with cisplatin (2 µg/mL) for 48 h were subjected to immunoblotting analysis with the indicated antibodies. The protein band intensities were estimated using ImageJ software with reference to the GAPDH control (γ-H2AX/GAPDH) and presented below the blot. F A549 cells were treated with the indicated concentrations of USP28 inhibitor (AZ1) with either vehicle or cisplatin (2 µg/mL) for 48 h and subjected to immunofluorescence analysis to estimate γH2AX foci formation. Green, γH2AX; blue, nucleus stained by DAPI. Scale bar = 100 µm. The right panel depicts the percentage of γH2AX-positive cells. Data are presented as the mean and standard deviation of three independent experiments (n = 3). G A549 cells were treated with cisplatin (2 µg/mL) for 48 h. Flow cytometry analysis was performed to analyze annexin-V and PI positive cells and graphically represented. Data are presented as the means and standard deviations of 3 independent experiments. H The effect of USP28 depletion or USP28 inhibitor (AZ1) on MEK pathway in A549 cells treated with cisplatin (2 µg/mL) by western blotting with indicated antibodies. GAPDH was used as the internal loading control

Article Snippet: Flag-tagged USP28 (Addgene #15665) and HA-tagged Ubiquitin (Addgene #18712) plasmids were purchased from Addgene.

Techniques: Western Blot, Expressing, Concentration Assay, CCK-8 Assay, Standard Deviation, Flow Cytometry, Staining, Immunofluorescence, Software

Loss of US28 inhibits tumorigenesis in vitro and in vivo. Mock control, USP28-KO, and USP28-KO cells reconstituted with either USP28 or MAST1 were used to perform the following experiments. The cells from (5A) were treated with either vehicle or cisplatin and were subjected to the following experiments . A Colony formation was measured after 14 days in A549 cells . The colony numbers were quantified and are presented graphically. Scale bar, 500 µm. B The transwell cell invasion assay was performed with the groups mentioned in A549 cells. The number of invaded cells were quantified using ImageJ software and represented graphically. Data are presented as the means and standard deviations of 3 independent experiments. Scale bar, 100 µm. C The migration potential of above mentioned groups was assessed by an in vitro scratch assay in A549 cells. The migration potential was quantified by ImageJ software and are presented graphically. Scale bar, 200 µm. Data are presented as the means and standard deviations of 3 independent experiments. D Xenografts were generated by subcutaneously injecting the mentioned cell groups into the right flanks of NSG mice (n = 4/group). Mice were i.p. injected with either saline (vehicle) or cisplatin (2 mg/kg) twice a week beginning 7 days after xenograft implantation, and tumor size was monitored. Tumor volumes were recorded, and tissues were stored for IHC experiments. The right panel shows the tumors excised from the mice after the experiment. E Tumor volume and tumor weight were measured and are presented graphically. Data are presented as the mean and standard deviation (n = 4 mice per group). Statistical power is 80% and was calculated post experiment using G*Power software. Two-way ANOVA followed by Tukey's post-hoc test was used, and the exact P values are indicated on the figures ( P < 0.05, P < 0.01, P < 0.001, P < 0.0001 were considered as significant, and P > 0.05 considered as non-significant). F Xenograft tumors were embedded in paraffin and sectioned. IHC analyses were performed with the indicated antibodies. Scale bar = 30 µm

Journal: Cellular and Molecular Life Sciences

Article Title: USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells

doi: 10.1007/s00018-024-05187-2

Figure Lengend Snippet: Loss of US28 inhibits tumorigenesis in vitro and in vivo. Mock control, USP28-KO, and USP28-KO cells reconstituted with either USP28 or MAST1 were used to perform the following experiments. The cells from (5A) were treated with either vehicle or cisplatin and were subjected to the following experiments . A Colony formation was measured after 14 days in A549 cells . The colony numbers were quantified and are presented graphically. Scale bar, 500 µm. B The transwell cell invasion assay was performed with the groups mentioned in A549 cells. The number of invaded cells were quantified using ImageJ software and represented graphically. Data are presented as the means and standard deviations of 3 independent experiments. Scale bar, 100 µm. C The migration potential of above mentioned groups was assessed by an in vitro scratch assay in A549 cells. The migration potential was quantified by ImageJ software and are presented graphically. Scale bar, 200 µm. Data are presented as the means and standard deviations of 3 independent experiments. D Xenografts were generated by subcutaneously injecting the mentioned cell groups into the right flanks of NSG mice (n = 4/group). Mice were i.p. injected with either saline (vehicle) or cisplatin (2 mg/kg) twice a week beginning 7 days after xenograft implantation, and tumor size was monitored. Tumor volumes were recorded, and tissues were stored for IHC experiments. The right panel shows the tumors excised from the mice after the experiment. E Tumor volume and tumor weight were measured and are presented graphically. Data are presented as the mean and standard deviation (n = 4 mice per group). Statistical power is 80% and was calculated post experiment using G*Power software. Two-way ANOVA followed by Tukey's post-hoc test was used, and the exact P values are indicated on the figures ( P < 0.05, P < 0.01, P < 0.001, P < 0.0001 were considered as significant, and P > 0.05 considered as non-significant). F Xenograft tumors were embedded in paraffin and sectioned. IHC analyses were performed with the indicated antibodies. Scale bar = 30 µm

Article Snippet: Flag-tagged USP28 (Addgene #15665) and HA-tagged Ubiquitin (Addgene #18712) plasmids were purchased from Addgene.

Techniques: In Vitro, In Vivo, Invasion Assay, Software, Migration, Wound Healing Assay, Generated, Injection, Saline, Standard Deviation

(A, B) Usp28 (A) and 53bp1 (B) mRNA levels in wild-type or Pkd1-null NIH3T3 cells, at various time points after serum re-addition (n = 3). Data are presented as means ± SEM. Two-way ANOVA with Holm–Sidak’s multiple comparisons test. (C, D) Representative images from Pkd1- null cells transfected with the indicated constructs and GFP at 24 h after serum re-addition (C). GFP + cells (green, insets) were evaluated for the presence or primary cilia via Arl13b (red) staining (C). Serum-induced deciliation rates are shown as best-fits with 95% confidence limits in indicated cell types (n = 3) (D). Scale bars: 5 μm. Data are presented as means ± SEM. Two-way ANOVA with Holm–Sidak’s multiple comparisons test. All comparisons were performed against the control group time points ( NIH3T3 Pkd1-KO transfected with scrambled siRNA, red curve). Color of the asterisks indicates comparison of the respective color group with the control group. ** P < 0.01, *** P < 0.001, **** P < 0.0001. (E, F) Representative images from wild-type NIH3T3 cells transfected with the indicated constructs and GFP at 24 h after serum re-addition. GFP + cells (green, insets) were evaluated for the presence or primary cilia via Arl13b (red) staining (E). Serum-induced deciliation rates are shown as best-fits with 95% confidence limits in indicated cell types (n = 3) (F). Scale bars: 5 μm. All comparisons were performed against the control group time points (NIH3T3 transfected with pcDNA3 , black curve). Color of the asterisks indicates comparison of the respective color group with the control group. Data are presented as means ± SEM. Two-way ANOVA with Holm–Sidak’s multiple comparisons test. * P < 0.05, ** P < 0.01, **** P < 0.0001.

Journal: Life Science Alliance

Article Title: Loss of polycystins suppresses deciliation via the activation of the centrosomal integrity pathway

doi: 10.26508/lsa.202000750

Figure Lengend Snippet: (A, B) Usp28 (A) and 53bp1 (B) mRNA levels in wild-type or Pkd1-null NIH3T3 cells, at various time points after serum re-addition (n = 3). Data are presented as means ± SEM. Two-way ANOVA with Holm–Sidak’s multiple comparisons test. (C, D) Representative images from Pkd1- null cells transfected with the indicated constructs and GFP at 24 h after serum re-addition (C). GFP + cells (green, insets) were evaluated for the presence or primary cilia via Arl13b (red) staining (C). Serum-induced deciliation rates are shown as best-fits with 95% confidence limits in indicated cell types (n = 3) (D). Scale bars: 5 μm. Data are presented as means ± SEM. Two-way ANOVA with Holm–Sidak’s multiple comparisons test. All comparisons were performed against the control group time points ( NIH3T3 Pkd1-KO transfected with scrambled siRNA, red curve). Color of the asterisks indicates comparison of the respective color group with the control group. ** P < 0.01, *** P < 0.001, **** P < 0.0001. (E, F) Representative images from wild-type NIH3T3 cells transfected with the indicated constructs and GFP at 24 h after serum re-addition. GFP + cells (green, insets) were evaluated for the presence or primary cilia via Arl13b (red) staining (E). Serum-induced deciliation rates are shown as best-fits with 95% confidence limits in indicated cell types (n = 3) (F). Scale bars: 5 μm. All comparisons were performed against the control group time points (NIH3T3 transfected with pcDNA3 , black curve). Color of the asterisks indicates comparison of the respective color group with the control group. Data are presented as means ± SEM. Two-way ANOVA with Holm–Sidak’s multiple comparisons test. * P < 0.05, ** P < 0.01, **** P < 0.0001.

Article Snippet: lentiCRISPRv2-puro was a gift from Brett Stringer (plasmid # 98290; http://n2t.net/addgene:98290 ; RRID:Addgene_98290; Addgene). pDZ Flag USP28 was a gift from Martin Eilers (plasmid # 15665; http://n2t.net/addgene:15665 ; RRID:Addgene_15665; Addgene). pX330 p53 was a gift from Tyler Jacks (plasmid # 59910; http://n2t.net/addgene:59910 ; RRID:Addgene_59910; Addgene). pcDNA3 flag p53 was a gift from Thomas Roberts (plasmid # 10838; http://n2t.net/addgene:10838 ; RRID:Addgene_10838; Addgene). pcDNA5-FRT/TO-eGFP-53BP1 was a gift from Daniel Durocher (plasmid # 60813; http://n2t.net/addgene:60813 ; RRID:Addgene_60813; Addgene).

Techniques: Transfection, Construct, Staining

(A, B) Efficiency of Usp28 siRNA was validated via Western blot after transfection with scrambled siRNA or increasing amounts of Usp28 siRNA (15, 30, and 50 nM) (A) and via immunofluorescence for USP28 (red) in Pkd1 -null NIH3T3 cells (B). (C, D) Efficiency of 53bp1 siRNA was validated via Western blot after transfection with scrambled siRNA or 50 nM 53bp1 siRNA (C) and via immunofluorescence for 53BP1 (red) in Pkd1 -null NIH3T3 cells (D). Scale bars: 5 μm. Source data are available for this figure.

Journal: Life Science Alliance

Article Title: Loss of polycystins suppresses deciliation via the activation of the centrosomal integrity pathway

doi: 10.26508/lsa.202000750

Figure Lengend Snippet: (A, B) Efficiency of Usp28 siRNA was validated via Western blot after transfection with scrambled siRNA or increasing amounts of Usp28 siRNA (15, 30, and 50 nM) (A) and via immunofluorescence for USP28 (red) in Pkd1 -null NIH3T3 cells (B). (C, D) Efficiency of 53bp1 siRNA was validated via Western blot after transfection with scrambled siRNA or 50 nM 53bp1 siRNA (C) and via immunofluorescence for 53BP1 (red) in Pkd1 -null NIH3T3 cells (D). Scale bars: 5 μm. Source data are available for this figure.

Techniques: Western Blot, Transfection, Immunofluorescence

Review

Structured Review

Images

Similar Products

Image Search Results